The MBE course is based at and managed by faculty of the Institute of Biotechnology, with the expert guidance of industry sector specialists, each of whom takes responsibility for the design of specific taught modules.
Cambridge is the home of Europe's largest biotech cluster and the course draws heavily on the expertise of executives from local and national businesses, many of whom have strong interest in furthering the education of the next generation of life science business development talent and bio-entrepreneurs. Each year over 90 individuals from companies engage with the course, providing scientific, technical and managerial insights through their lectures, as well as a diversity of practical case examples and internship opportunities for MBE students. The course is further enhanced by specialist input from the University’s academic researchers, many of whom also have significant business experience, and by a close association with Judge Business School, which provides several management training elements.
Professor Chris Lowe OBE, Director
Professor Chris Lowe is Head of the Institute of Biotechnology and University Professor of Biotechnology. He is renowned for his work in healthcare biotechnology, particularly the high-value low-volume sectors of biopharmaceuticals, sensors and diagnostics and microbial technology. Chris’ work is highly multidisciplinary and spans fundamental science to strategic and applied science, much of which has significant commercial application. Chris interests and achievements have been widely recognised , including: Queen's Award for Technological Achievement: Queen's Anniversary Prize for Higher and Further Education: BBSRC Innovator of the Year and ‘Most Entrepreneurial Scientist of the UK’.
Professor Sabine Bahn, Director
Professor Sabine Bahn, Director of the Cambridge Centre for Neuropsychiatric Research, is a practising psychiatrist and leading research scientist. Her main research interests are to understand the molecular basis of neuropsychiatric disorders, with a focus on schizophrenia and mood disorders. She co-founded Psynova Neurotech Ltd. which together with Rules Based Medicine Inc. launched the first blood test aiding in the early diagnosis of Schizophrenia, before being acquired by NASDAQ-listed Myriad Genetics. Professor Bahn continues to be director and chief scientific officer for Psynova Neurotech as well as Senior Medical Director for Neuropsychiatric Disorders for Myriad RBM and Myriad Genetics. Sabine also holds a Chair in Translational Neuropsychiatry at the Erasmus Medical Centre in Rotterdam, NL.
Dr Linda Allan, Academic Director
Prior to joining the MBE programme in 2005, Linda was CEO of a company that provided technology-focused executive education events in Cambridge and London. During PhD studies and post-doctoral research at the Medical Research Council Biochemical Parasitology Unit and the Cambridge Department of Biochemistry, University of Cambridge, Linda studied the parasite Trypanosoma brucei , characterising monoclonal and polyclonal antibodies to elucidate the immunological basis of host / parasite interactions, Thereafter she lived in Massachusetts for several years, during which time she developed an interest in factors influencing high tech companies and their development.
Catherine King, Programme Administrator
Catherine who joined the MBE course as MBE Programme Administrator in December 2011, she holds a degree in Information Technology and Computing. Prior to this role she worked as a Database Administrator and Web Developer for cintelliq ltd and an information analyst at the Royal Marsden Hospital.
Dr Ken Seamon
Ken brings a wealth of experience of USA and European biotech to the programme. In his role as Development Director, Science at the Cambridge Cancer Centre he is working to progress the development of scientific interactions across Cambridge. Formerly Ken was Vice President, Regulatory Affairs at Amgen Corp., with responsibility for the Regulatory CMC Group as well as for developing policy for Follow on Biologics and Biosimilars. Earlier in his career, Ken was Senior Vice President, Drug Development at Immunex Corporation, Seattle, Washington State and spent 13 years with the Food and Drug Administration (FDA), latterly as the Director of the Office of Therapeutics Research and Review and Associate Director for Research at the Center for Biologics Research and Review at Bethesda, Maryland.
Dr William Bains
William worked with the PA Consulting Group for eight years and later as Head of the Science team at the UK venture capital group Merlin Biosciences from 1996-2000, providing the principle scientific input into raising the €247M Merlin Biosciences Fund. In 2000 he founded Amedis Pharmaceuticals, a product-oriented drug discovery company with platform technologies in proprietary chemistry and artificial intelligence. He is the founder of Rufus Scientific, an advisory consultancy for those exploiting breakthrough science and Opal Drug Discovery, a pharmaceutical IP exploitation company. William is the author of numerous patents, four books: Venture Capital and the European Biotechnology Industry; Genetic Engineering for Almost Anybody; Artificial Intelligence from A to Z; and Biotechnology from A to Z, now in its third edition and translated into several languages, as well as over 60 research articles. He has an abiding interest in astrobiology and spends a proportion of his time working with like-minded colleagues at MIT.
Dr Cathy Prescott
Dr Cathy Prescott brings over 20 years of experience in research, management and business within the life-science and venture capital sectors. She is the Founder Director of Biolatris Ltd. a specialist biotech-consultancy and co-founder director of Quartet Innovation Partners Ltd which develops innovative financial products for the healthcare sector. She is also a non-executive director for the regenerative medicine company Videregen and an advisory board member to Trakcel Ltd and to the WPI Life Sciences committee (US). Cathy is a respected opinion leader within the stem cell and regenerative medicine business sector, and co-editor of the book ‘The Delivery of Regenerative Medicines and their Impact on Healthcare’.
Prior to Biolatris, Cathy spent seven years as a director for the venture capital firm Avlar BioVentures and was a non-executive director to several portfolio companies. She was formerly head of drug discovery at Ribotargets Ltd and assistant director and group leader for SmithKline Beecham. Cathy held post-doctoral fellowships at Max Delbruick Centre for Molecular Medicine and Max Planck Institute for Molecular Genetics, both in Berlin, and Brown University, USA. Cathy holds a DPhil from the University of Oxford.
With 36 years of biopharmaceutical industry and consulting experience, Keiron is an acknowledged global drug development, pricing and market access expert. He is also a successful entrepreneur and in 2012 sold the healthcare strategy consultancy PriceSpective, a company he founded and guided for almost ten years, to ICON plc. Since then he has expanded his other business interests in therapeutic development and in personal growth companies, notably following his absolute passion for improving cognitive health when he founded MyCognition . Keiron initiated the department’s Biopharmaceutical Market Access and Pricing Strategy professional practice programme, and in 2011-12 led the UK Chapter of the Entrepreneur’s Organisation, an association encompassing more than 8,000 entrepreneurs worldwide.
Dr David Hampton
David is a biomedical research scientist and entrepreneur in medical device innovation and global business development. David is founder and CTO of CamStent Ltd, an MBE programme spinout, and the managing partner at Acacia Designs BV and Stone Bridge Biomedical BV. He was preciously an elected Research Director and Fellow at Medtronic’s Bakken Research Center in Maastricht, and is a founding member of the medical design partnership bioMRC. His academic background includes the MBE, with distinction, a certificate in management science from Stanford University, doctorate and master’s degrees in biomedical engineering from Northwestern University, and a bachelor’s degree, cum laude, in physics and applied mathematics from Vanderbilt University.
Dr Fiona Marshall
Fiona is a molecular pharmacologist with more than 20 years of experience in pharmaceutical research, particularly in the field of progressing novel genomic targets through to drug discovery. She is founder and CSO of Heptares Therapeutics Ltd, a drug discovery company spun-out from the MRC Laboratory of Molecular Biology, that applies structural knowledge of G-protein coupled receptors to the design and development of drug molecules. Dr Marshall was previously Director of Pharmacology, Europe, for Millennium Pharmaceuticals and spent 12 years at GlaxoSmithKline, where she held a number of senior positions, including Head of the Department of Molecular Pharmacology and Head of G-Protein Coupled Receptor Research.
Dr Tim Allsopp
Tim is Head of Cell Improve Outreach Programme at Neusentis, a Pfizer Research unit. Tim has extensive experience in the biotech sector, founding, building, resourcing and managing change in small to medium sized enterprises, and in leveraging public sector opportunities to resource product development strategies. Tim has developed experimental strategies and managed discovery to innovation, putting into practice the delivery of products from the biology of human cells. He holds a B.Sc. in Zoology and PhD in Biophysics, Cell & Molecular Biology from the University of London.